ViGeneron was founded in 2017 as a spin-off from Ludwig Maximilian University of Munich (LMU Munich). The company is focused on developing innovative gene therapies based on its proprietary technology platforms designed to improve the delivery and effectiveness of genetic treatments. ViGeneron primarily targets unmet medical needs in inherited retinal diseases and other ophthalmic disorders through its in-house gene therapy programs. In addition, the company collaborates with partners to apply its technologies to a broader range of therapeutic indications, aiming to advance next-generation treatments for genetic diseases.